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Abstract
Monocyte chemoattractant protein-1 (MCP-1), a chemokine secreted by neurons and astrocytes following stroke is known
to aggravate ischemia-related damage. Previous studies revealed that MCP-1-deficient mice develop smaller infarcts and
have an improved neurological outcome, whereas mice overexpressing MCP-1 show worsened brain damage and impaired
neurological function. The aim of the present study was to elucidate the molecular background of the enhanced recovery in
MCP-1-deficient mice after stroke. For this purpose, we (1) performed expression analyses on crucial post-stroke related
inflammatory genes in MCP-1-deficient mice compared to wildtype controls, (2) analyzed a possible impact of MCP-1 on
astrocyte activation (3) investigated the cellular origin of respective inflammatory cytokines and (4) analyzed the impact of
MCP-1 secretion on the migration of both neutrophil granulocytes and T-cells. Here we report that MCP-1-deficiency leads
to a shift towards a less inflammatory state following experimental occlusion of the middle cerebral artery including an
impaired induction of interleukin-6, interleukin-1b and granulocyte-colony stimulating factor expression as well as a
subsequent diminished influx of hematogenous cells. Additionally, MCP-1-deficient mice developed smaller infarcts
36 hours after experimental stroke. Investigations revealed no differences in transcription of tumor necrosis factor-a and
astrogliosis 12 and 36 hours after onset of ischemia. These novel results help to understand post ischemic, inflammatory
mechanisms and might give further arguments towards therapeutical interventions by modulation of MCP-1 expression in
post stroke inflammation.
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Introduction
Increasing evidence suggests that cytokine mediated post stroke
inflammation and subsequent influx/action of hematogenous
leukocytescontributestothedevelopmentofischemicbraindamage
and might, therefore, be a promising target for neuroprotective
therapies [1]. Regarding the conclusions of previous studies, clot-
lysing treatment of stroke could be more beneficial in combination
with neuroprotective and/or pro-regenerative treatments [2].
Cerebral ischemia is a multiphasic event involving acute and
prolonged inflammatory processes, which play a pivotal role in
disease pathogenesis as well as having a significant impact on
neurological outcome [3]. Within the first hours after onset of
ischemia affected brain cells produce and secrete proinflammatory
cytokines including monocyte chemoattractant protein-1 (MCP-1),
interleukin-6 (IL-6), interleukin-1b (IL-1b), tumor necrosis factor-a
(TNF-a) and granulocyte-colony stimulating factor (G-CSF) [4,5].
Monocyte chemoattractant protein-1 (also known as CCL-2) is
chemotactic for monocytes, hematogenous macrophages, neutro-
phil granulocytes, memory T-lymphocytes and natural killer cells
[6,7]. Following cerebral ischemia astrocytic and neuronal MCP-1
secretion within the injured tissue is rapidly induced [8,9].
Importantly, mice lacking MCP-1 show, along with impaired
leukocyte influx and reduced infarct volume, an improved
neurological outcome [10], whereas overexpression of MCP-1
leads to exacerbated brain injury and increased migration of
inflammatory cells [11]. Since the molecular background of
neuroprotection in MCP-1-deficient mice still remains poorly
understood, the present study aimed to clarify the influence of
MCP-1-signaling on the expression of crucial inflammatory
mediators IL-6, IL-1b, TNF-a and G-CSF, reactive astrogliosis,
infarct size development and the post ischemic migration of
neutrophil granulocytes and T-cells.
Materials and Methods
All animal studies and procedures have been approved by the
local governmental authorities (Landesamt fu ¨r Natur, Umwelt und
Verbraucherschutz, NRW, Germany, AZ 8.87-50.10.36.09) and
were conducted in accordance with the European Convention for
Animal Care and Ethical Use of Laboratory Animals. The number
of animals was kept to a minimum needed.
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Animals were bred and housed in a pathogen-free environment
under standard laboratory conditions with a 12 h/12 h light-dark
cycle and were allowed free access to food and water. Fifteen male
16–18 week old C57BL/6J (Charles River, Sulzfeld, Germany)
and fifteen male MCP-1-deficient mice (The Jackson Labs, Bar
Harbor, Maine, USA) were subjected to experimental cerebral
ischemia. Animals were sacrificed 12 and 36 hours following
MCAO. Two separate groups of sham-operated mice were used as
controls. Generation of MCP-1-knock-out mice has been de-
scribed before [12]. MCP-1-deficient and wildtype animals were
backcrossed at least eight times to obtain a pure C57BL/6J
background. Tail-clipped DNA was used for genotyping by PCR
according to the genotyping protocols for MCP-1 (Jackson Labs).
Transient focal cerebral ischemia
Animals weighing 25–30 g were anesthetized and maintained
with 1.5% isoflurane in 30% O2/70% N2O. Body temperature was
controlled using a rectal temperature probe and maintained at
37uC60.5uC by a thermostat-controlled heated blanket. Experi-
mental stroke was induced by occlusion of the middle cerebral
artery (MCAO), using a modified intraluminal technique [13].
MCAO was performed with a silicone resin-coated (Xantopren;
Haeraeus, Dormagen, Germany) 8-0 nylon monofilament (Ethilon;
Ethicon, Norderstedt, Germany) which was introduced into a small
incision of the left commoncarotid artery and advanced distal to the
carotid bifurcation for temporary occlusion of the middle cerebral
artery (30 min). Regional cerebral blood flow (CBF) was continu-
ously monitored using a laser doppler probe (Periflux 5001;
Perimed, Stockholm, Sweden) to verify ischemia and reperfusion.
The laser doppler probe was positioned, after an incision was made
in the temporal muscle overlapping skin, on the superior portion of
the temporal bone (centre of ischemic area). The occlusion was
established when the CBF dropped below 20% of the pre-MCAO
flow-value. All mice showed appropriate signs for successful
operation (disturbance in locomotion and/or flexion of the effected
affected limb) and were included in the subsequent experimental
procedures.
Tissue preparation
Both, sham operated mice and animals subjected to MCAO
used for subsequent experiments (n=10 per group) were
terminally anesthetized with ketamine/xylazine and perfused
intracardially with 0.9% NaCl. Brains were quickly removed,
embedded in TissueTek (Sakura Finetek, the Netherlands), frozen
on dry ice and stored at 280uC. Mice used for immunohisto-
chemical staining (n=5 per group) were perfused with 4%
paraformaldehyde and brains were postfixed for 3 h in 4% PFA
and 10% sucrose overnight (4uC) before embedding and freezing.
For both, expression studies and immunohistochemical staining
10 mm thin coronal sections through the infarcted area (approx-
imately bregma 1 mm to 0 mm) were cut using a cryostat (Leica
CM 3050, Nussloch, Germany). Specimen used for subsequent
gene expression analyses were mounted on polyethylenenaphtalate
(PEN) membrane coated slides (PALM MicroLaser Systems,
Germany); sections for immunohistochemical analysis were
mounted on glass slides (SuperFrost, Langenbrinck, Germany).
Laser capture microdissection
PEN foil glass slides containing specimen for laser capture
microdissection were fixed immediately after sectioning, in 96%
ethanol at 220uC for 5 min and air-dried for 1 min. Toluidine
blue staining was carried out to identify the ischemic area within
the ipsilateral hemisphere. Staining was done with a 0.1%
Toluidine blue (Sigma-Aldrich, Munich, Germany)/0.1 M sodium
phosphate buffered solution (pH 5.5) for 1 min, followed by
dehydration in graded ethanol dilutions (70%, 96%, 100%, 30 s
each).
Once air-dried, slides were stored at 280uC until further use.
Three different areas of interest were isolated using a Zeiss/PALM
LMD microscope (Carl Zeiss MicroImaging GmbH, Germany):
the ipsilateral cortex (covering the primary motor- and primary
somatosensory-cortex), the ipsilateral ischemic area and the
contralateral caudate putamen (Fig.1 A). Regions of interest were
isolated and collected in microfuge caps containing 45 ml of RNA
extraction buffer RLT (Qiagen, Hilden, Germany). To avoid
RNA-degradation, lysis buffer was supplemented with 2-mercap-
toethanol (143 mM, Sigma-Aldrich, Munich, Germany). Three
areas of 20 brain slices from each animal were cut and collected in
separate caps for subsequent analysis of gene expression.
RNA extraction, quality assessement and cDNA-synthesis
Total RNA extraction was carried out using the RNA isolation
kit (RNeasy micro kit, Qiagen, Hilden, Germany) following the
protocol provided for RNA extraction from microdissected tissue.
RNA quality and integrity was measured with the Agilent
Bioanalyzer System (Agilent 2100 Bioanalyzer, RNA 6000
PicoLabChip Kit, Agilent Technologies, Santa Clara, CA,
USA). RNA samples with a RNA integrity number of six and
greater (see Agilent evaluation criterion) were used for cDNA
synthesis and subsequent expression analyses (Fig. 1 B). First
strand cDNA synthesis was performed using a reverse transcrip-
tion kit (QuantitectH Reverse Transcription Kit, Qiagen, Hilden,
Germany) following the manufactures procedure.
Quantitative real-time polymerase chain reaction
All primers were purchased from Qiagen (QuantiTect Assays,
Hilden. Germany) and were as follows: glycerinaldehyde-3-phos-
phate-dehydrogenase (QT01658692); interleukin-1b (QT01048355);
tumor necrosis factor-a (QT00104006); interleukin-6 (QT00098875)
and granulocyte-colony stimulating factor (QT00105140). To
determine mRNA levels of GAPDH, IL-1b,T N F - a,I L - 6a n dG -
CSF, semi-quantitative real-time polymerase chain reactions (qRT-
PCR) were performed using SYBR-green fluorescence on ABI
PRISMH 7700 RT-PCR-System (Applied Biosystems, Foster City,
CA, USA).
Expression analysis
RT-PCR data were normalized and related for each individual
sample to the expression of GAPDH as a housekeeping gene.
Relative expression analysis of target genes was carried using the
comparative cycle threshold method (DDCT). Calculations were
performed with the relative expression software tool REST-MCS
version 2, which uses the efficiency-corrected comparative crossing
point method to estimate a sample expression ratio [14,15].
Expression changes were reported as a difference relative to the
normalized samples of sham-operated animals. In order to reveal
possible differences between control animals, an additional
comparison of normalized expression patterns between sham-
operated MCP-1-deficient and wildtype mice was performed.
Immunohistochemical staining
Glass mounted coronal sections were postfixed in 4% buffered
PFA for 15 min, endogenous peroxidase was blocked by
incubation in 3% H2O2/Methanol for 10 min and nonspecific
protein binding was inhibited by incubation with Blocking
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following antibodies were applied for antigen detection (4uC,
overnight): monoclonal antibody directed against microglia and
macrophages anti-F4/80, raised in rat (1:500, Biozol Diagnostica,
Eching, Germany), anti-neutrophil antibody 7/4, raised in rat
(1:200, Serotec, Duesseldorf, Germany), monoclonal anti-GFAP
antibody directed against astrocytes, raised in mouse (1:200,
Sigma-Aldrich, St. Louis, MO, USA), for detection of neurons
monoclonal anti-neuronal nuclei (NeuN), raised in mouse (1:300,
Chemicon Int., Temecula, CA, USA), polyclonal anti-CD3
antibody directed against T-cells, raised in hamster (1:100, BD
Biosciences, Erembodegem, Belgium), polyclonal anti-G-CSF
antibody (1:200, Abcam, Cambridge, UK), polyclonal anti-IL-6
antibody (1:100, Abcam) and a polyclonal anti-IL-1b antibody
(1:100, Abcam). G-CSF, IL-6 and IL-1b antibodies were raised in
rabbit. To detect both anti-neutrophil and anti-F4/80-antibodies
we used a biotinylated goat anti-rat antibody (1:200, Jackson Labs,
West Grove, PA, USA) for 45 min at room temperature. For
signal amplification of 7/4 and F4/80 signal, brain slices were
incubated with horseradish peroxidase/streptavidin (1:100,
DAKO, Glostrup, Denmark) for 45 min and biotinyl tyramide,
(1:100) for 10 min at room temperature. Both microglia and
neutrophils were visualized by a streptavidin/fluorescent dye
(AlexaFluor488, Molecular Probes, Leiden, the Netherlands). To
visualize astrocytes and neurons we used a fluorescent dye-
conjugated goat anti-mouse antibody (AlexaFluor488 goat anti-
mouse, Molecular Probes). To detect CD-3-antibodies, brain slices
were incubated with a biotinylated goat-anti hamster antibody
(1:200, 45 min, room temperature, Jackson Laboratories) and
visualized with a streptavidin/fluorescent dye at a dilution of 1:100
for 45 min at room temperature (AlexaFluor488, Molecular
Probes). To detect G-CSF, IL-6 and IL-1b-antibodies a fluores-
cent dye-conjugated goat-anti rabbit secondary antibody was
used at a dilution of 1:100 for 45 min at room temperature
(AlexaFluor594, Molecular Probes). Nuclear counterstaining was
done using a fluorescent-preserving mounting medium containing
49, 6-diamidino-2-phenylindole (DAPI) (Vector, Burlingame, CA,
USA). Immunostaining was visualized with a fluorescent micro-
scope (Leica DM microscop, Bensheim, Germany) with appropri-
ate filter sets for AlexaFluor594, AlexaFluor488 and DAPI.
Digitizing was done with a Diagnostic SPOT Advanced Camera
System (Diagnostic Instr., Sterling Heights, USA). Quantification
of IHC-data was carried out by counting cells showing a positive
fluorescence signal for IL-6, IL-1b, TNF-a or G-CSF within the
Figure 1. Laser capture microdissection was performed on PEN-membrane mounted and toluidine-stained brain sections. A: Three
areas, namely cerebral cortex (cor), infarct core (inf) and contralateral striatum (cnl) were cut out of specimen and total RNA for subsequent analyses
was extracted. B: Total RNA integrity of each sample was measured with an Agilent 2100 Bioanalyzer (exemplary data shown). Distinct peaks for 18S
and 28S rRNA indicate intact RNA. Only total RNA with a RNA integrity number greater than or equal to 6 was used for subsequent reverse
transcription and qRT-PCR. C: Real-Time PCR data showed no significant differences of IL-6, IL-1b, TNF-a and G-CSF expression between wildtype and
MCP-1-deficient control animals. D: Infarct size assessed 12 and 36 hours after MCAO. Lesion volume is expressed as percentage of the ipsilateral
hemisphere. Values represent mean 6 SD, *p,0.05.
doi:10.1371/journal.pone.0025863.g001
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numbers in relation to the total number of DAPI-positive cells.
Infarct size measurement
Comparison of ischemic brain lesion size was carried out using
two toluidine stained brain sections of each animal (bregma
,0.5 mm). Infarct area and the size of the ipsilateral hemisphere
were measured using a standard computer assisted analysis
technique. Infarct size was calculated as follows: infarcted area/
ipsilateral hemisphere*100 and shown as percentage of the
ipsilateral hemisphere. Differences between lesioned area sizes of
MCP-1-deficient and wildtype animals were evaluated by two-way
ANOVA followed by Bonferronis post-hoc test using GraphPad
Prism software 5.01 (GraphPad Software, La Jolla, CA, USA).
Infarct sizes are presented as mean 6 SD and were regarded to be
significant if p,0.05.
Evaluation of reactive astrogliosis
To determine whether MCP-1-deficiency has an influence on
astrocyte activation, a separate PFA-fixed coronal section (bregma
approximately 0.5 mm) of each animal was stained according to the
used protocol for GFAP-immunohistochemistry. GFAP-antibodies
were visualized with AlexaFluor594 goat-anti mouse antibodies
(Vectashield Labs), nuclear counterstain was done with DAPI.
Whole hemisphere images of GFAP-stained sections were taken
with a Nikon Eclipse 80i microscope (Nikon GmbH, Duesseldorf,
Germany) and the Stereo Investigator Software (MicroBrightField
Inc.,Williston, VT, USA). Astrocyte-stained sections were analyzed
with respect to differences in immunoreactivity and morphology
between wildtype and MCP-1-deficient mice.
Quantification of migrated neutrophil granulocytes and
T-cells
Quantification of migrated neutrophil granulocytes and T-cells
was performed by counting and averaging absolute cell numbers
within the ipsilateral cortex (Fig.1 A ‘‘cor’’) of 8 separate brain
sections per animal. Differences between neutrophil and T-cell
counts were evaluated by the analysis of variance followed by
Bonferronis post-hoc test using GraphPad Prism software. Results
are presented as mean 6 SD and were regarded to be significant if
p,0.05.
Results
Expression in sham-operated animals
In order to exclude differences of wildtype and MCP-1-deficient
constitutional gene expression we compared IL-6, IL-1b, TNF-a
and G-CSF mRNA concentration in samples of sham-operated
control mice. Data revealed no significant differences of IL-6, IL-
1b, TNF-a and G-CSF expression between wildtype and MCP-1-
deficient control animals (Fig.1 C).
Infarct size
Twelve hours following cerebral ischemia no significant
difference of infarct size between wildtype (22.6364.24%) and
MCP-1-deficient mice (20.0864.59%) could be detected (Fig.1 D).
In contrast, 36 hours following MCAO, lesion size was signifi-
cantly increased in wildtype (27.9867.05%) compared to MCP-1-
deficient animals (17.8064.79%, p,0.05).
MCP-1-deficiency has no impact on astrocyte activation
Since astrocytes are known to become activated as a response to
a variety of CNS pathologies [16] we investigated a possible
influence of MCP-1 on the reactive astrogliosis 12 and 36 hours
after cerebral ischemia. Comparing analyses of GFAP-stained
coronal sections showed no differences with respect to immuno-
reactivity and morphology between both investigated groups and
time-points. Activated astrocytes showed the common distribution
and activation primarily surrounding the infarcted core in both
wildtype and MCP-1-deficient mice (Fig.2).
MCP-1-deficiency impairs IL-6 expression
To investigate whether MCP-1 expression is associated with an
induction of IL-6, we measured and compared IL-6-mRNA
concentrations within three different brain areas of wildtype and
MCP-1-deficient mice. Twelve hours after onset of MCAO a
considerable induction of IL-6 was found within the cortex and
infarct core of wildtype animals. In contrast, MCP-1-deficient
animals showed a severely impaired IL-6 expression in both
ipsilateral cortex (p,0.01) and infarcted core (p,0.01, Fig.3 A, B,
C). Thirty-six hours after MCAO IL-6 expression patterns showed
no significant change compared to the earlier time-point in both
wildtype and MCP-1-deficient animals. IL-6 expression remained
elevated in both wildtype cerebral cortex (p,0.05) and infarcted
core, whereas samples of MCP-1-deficient mice showed almost no
IL-6 expression in all investigated areas (Fig.3 D, E, F-). Next, we
Figure 2. MCP-1-deficiency has no impact on astrocyte
activation. Whole hemisphere GFAP-stained images comparing the
activation of astrocytes between wildtype and MCP-1-deficient animals.
Analyses showed no differences with respect to immunoreactivity and
morphology between wildtype and MCP-1-deficient mice. GFAP
staining showed the common distribution and activation of astrocytes
reacting to oxygen deprivation. Astrogliosis occurred primarily sur-
rounding the infarcted core in both wildtype and MCP-1-deficient mice.
doi:10.1371/journal.pone.0025863.g002
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markers for neurons, astrocytes, microglia/macrophages and
neutrophil granulocytes. Double fluorescence analysis revealed
colocalizations of IL-6 with GFAP and NeuN within the ipsilateral
cerebral cortex and infarcted core indicating that IL-6 is
particularly expressed by astrocytes and neurons after cerebral
ischemia (Fig.4 A, B, C, D, E, F, G, H). In concordance with the
results of mRNA expression we found significantly reduced cell
numbers positive for IL-6 in MCP-1 deficient mice within the
ipsilateral cortex and the ischemic core at both investigated time-
points (Fig.5). Regarding the contralateral hemisphere, IL-6
positive cells increased in wildtype animals 12 hours after MCAO,
whereas cell counts remained on the level of the control group in
MCP-1-deficient mice at both time-points.
MCP-1-deficiency leads to an impaired expression of
IL-1ß
To investigate whether MCP-1 signalling determines post-ischemic
IL-1b regulation we compared relevant mRNA levels within the
three defined areas 12 and 36 hours after MCAO. In wildtype mice,
IL-1b was expressed on a significantly higher level within the cerebral
cortex (p,0.05) and the ischemic core (p,0.01) 12 hours after
MCAO (Fig.3 A, B). Data indicates that IL-1b induction is mainly
restricted to the infarcted core as mRNA-concentrations within the
cortex and the contralateral hemisphere were at a low level or even
downregulated. In contrast, 36 hours following MCAO IL-1b
expression was severely downregulated in both MCP-1-deficient
and wildtype animals and all investigated areas (Fig.3 D, E, F).
However, no significant differences between the two groups could be
observed. Immunohistochemical double staining revealed neurons as
main source of IL-1b (Fig.4 I, J, K, L). In wildtype mice, occasional
colocalization of IL-1b and astrocytic marker GFAP could be
detected but was entirely missing in MCP-1-deficient animals (not
shown). In concordance, IL-1b fluorescence signal intensity was
reduced in MCP-1-deficient animals compared to the wildtype group
(Fig.4 L), although IL-1b cell quantification showed no differences
between the investigated groups (Fig.5). Furthermore, in wildtype
animals no significant changes compared to the respective control
group could be observed except increased numbers of IL-1b
expressing cells within the contralateral hemisphere at 12 hours
(p,0.001) and the perilesional cortex 36 hours (p,0.05) following
MCAO.
TNF-a expression is not affected by MCP-1-deficiency
As expected, TNF-aexpression was upregulated following cerebral
ischemia. Admittedly, 12 and 36 hours after transient cerebral
ischemia TNF-a showed no significant differences between wildtype
mice and MCP-1-deficient animals (Fig.3 A, B, C). Thirty-six hours
Figure 3. IL-6, IF-1b, TNF-a and G-CSF mRNA expression within three defined microdissected areas. RT-PCR was performed to detect
and compare mRNA levels of wildtype and MCP-1-deficient mice within the cerebral cortex, infarcted core and contralateral striatum 12 hours (A2C)
and 36 hours (D2F) after focal transient ischemia. Data represent mean levels 6 SD of mRNA expression in wildtype and knock-out mice compared
to respective sham-operated mice. RT-PCR was repeated twice for each sample. *p,0.05; **p,0.01; ***p,0.001: statistically significant differences
between wildtype versus knock-out mice (ANOVA with Bonferronis post hoc-test).
doi:10.1371/journal.pone.0025863.g003
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main source of interleukin-6-synthesis. In MCP-1-deficient mice, IL-6 signal pattern also showed double positive signals colocalized with
astroctyes (D) and neurons (H) but with reduced intensity indicating a diminished IL-6 concentration on the translational level. Expression of IL-1b
within the ischemic core was mainly restricted to neurons (I2K) in both wildtype and MCP-1-deficient mice, the latter displaying a reduced IL-1b-
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investigated groups and showed no differences in comparison to the
earlier time point. Immunohistochemistry revealed neurons as the
main source of TNF-a. Quantitative analysis confirmed transcrip-
tional data as no difference in cell number could be observed except
within the infarcted core, which showed less TNF-a positive cells in
MCP-1-deficient animals 12 hours after MCAO (p,0.001, Fig.5).
G-CSF expression is affected by MCP-1
Following cerebral ischemia, upregulation of granulocyte
colony-stimulating factor has been reported in both rodents and
humans [17,18]. Therefore, we examined a possible influence of
MCP-1 signalling on the expression of G-CSF. Indeed, 12 and
36 hours after transient MCAO, G-CSF was induced and
upregulated in both wildtype and MCP-1-deficient mice (Fig.3).
Analysis within the ipsilateral cortex revealed a reduced induction
of G-CSF in MCP-1-deficient mice compared to the wildtype
group 12 hours (p,0.001) after MCAO. No significant difference
in G-CSF expression could be detected within the infarct core at
both investigated time-points. Furthermore, G-CSF was upregu-
lated within the contralateral hemispheres of both wildtype and
MCP-1-deficient mice. Thirty-six hours after onset of cerebral
ischemia G-CSF mRNA-concentration declined within the ipsilat-
eral hemisphere. However, expression patterns showed similar
characteristics compared to the earlier time-point showing an
elevated G-CSF expression in wildtype mice within the cerebral
cortex (p,0.05, Fig.3 D). Dual immunohistochemical staining
revealed astrocytes and both ramified and activated microglia as the
main source of G-CSF (Fig.4 M, N, O, P, Q, R, S, T). Quantitative
analysis showed few G-CSF-positive stained cells in sham-operated
mice (Fig.5). Twelve hours following MCAO, confirming transcrip-
tional data, cell numbers within the perilesional cortex increased in
both analyzed groups and declined 36 hours after cerebral
ischemia. Quantification within the infarcted core showed no
significant increase of G-CSF positive cells compared to the sham-
operated group except in MCP-1-deficient mice 12 hours after
Figure 5. Quantification of IL-6, IF-1b, TNF-a and G-CSF expressing cells. IL-6, IF-1b, TNF-a and G-CSF-positive cells as well as DAPI-positive
cells were counted 0, 12 and 36 hours following MCAO. Cell numbers are presented as percentage in relation to the total DAPI-positive cell number
within the respective area. Data are shown as mean6SD. *p,0.05; **p,0.01; ***p,0.001: statistically significant differences between wildtype versus
MCP-1-deficient animals (ANOVA followed by Bonferronis post hoc-test).
doi:10.1371/journal.pone.0025863.g005
fluorescence intensity confirming the results of the expression analyses (L). Shrinked cell morphology indicates apoptotic processes within the
infarcted core. Double immunofluorescence-staining also showed co-localization of G-CSF-positive cells and astrocytes (M2O), microglia (Q2S) and
occasionally, neurons (T). In MCP-1-deficient mice astrocytic G-CSF secretion was clearly diminished, visualized by the reduction of fluorescence signal
intensity reveals (P). Scale bar=25 mm.
doi:10.1371/journal.pone.0025863.g004
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changes of G-CSF-positive cells could be detected within the
contralateral hemisphere in both groups and time-points.
MCP-1-deficiency leads to a reduced influx of neutrophil
granulocytes and T-cells
As a result of oxygen deprivation and subsequent expression of
chemokines and cytokines, various hematogenous cells are
attracted into the ischemic tissue and influence the subsequent
inflammatory response. In this study, we analyzed whether the
altered expression of IL-6, IL-1b and G-CSF in MCP-1-deficient
mice has an influence on the post-stroke migration of neutrophil
granulocytes and T-cells. For this purpose, we counted and
compared the numbers of migrated neutrophil granulocytes and
T-cells within the ipsilateral cortex of wildtype and MCP-1-
deficient mice. We detected an accumulation of 7/4-positive cells
within the ipsilateral cortex and the meningeal layers in both
examined groups of animals (Fig.6 C). Cell number analysis
revealed a reduced influx of neutrophil granulocytes in MCP-1-
deficient mice 12 hours following MCAO (p,0.001, Fig.6 A).
Twelve hours after cerebral ischemia few T-cells could be seen
in both wildtype and MCP-1-deficient mice. The majority of
detected T-cells seemed to be in close vicinity to blood vessels or
attached to the respective endothelium (Fig.6 D). Quantitative
analyses revealed a significant difference 36 hours after MCAO as
T-cell numbers increased in wildtype but not MCP-1-deficient
mice (p,0.01).
Discussion
The mechanisms by which MCP-1 contributes to final infarct
size and neurological outcome after stroke remain largely
unknown. The present study investigated the influence of MCP-
1 signalling on the expression profile of stroke relevant
inflammatory cytokines, astrocytosis, lesion development and its
effects on the migration of neutrophil granulocytes and T-cells. As
development of infarct volume is completed 24 hours following
cerebral ischemia [19], we decided to investigate the expression
and secretion pattern of the questioned proteins 12 and 36 hours
after MCAO. Here, we report that MCP-1-deficiency impairs the
induction of IL-6, IL-1b and partially G-CSF early after cerebral
ischemia, resulting in a reduced influx of neutrophil granulocytes
and T-cells. Interestingly, we observed the altered inflammatory
response in MCP-1-deficient mice, particularly 12 hours after
cerebral ischemia, as the transcription rate of most of the
investigated genes declined and equalized between wildtype and
MCP-1-deficient mice 36 hours after MCAO. Importantly, a lack
of MCP-1 did not result in an impaired astrogliosis or varying
infarct size 12 hours following MCAO, concluding that dimin-
ished transcription of IL-6, IL-1b and G-CSF is not caused by
delayed astrocyte activation or smaller lesion size. In a previous
study, we found no differences in the infarct volume between
wildtype and MCP-1-mice during the early phase of lesion
development [9]. However, confirming the findings of the present
study, MCP-1-deficient mice showed significant smaller infarct
volumes 48 hours after MCAO. The role of endogenous
interleukin-6 in post-stroke inflammation and development of
brain tissue damage still remains unclear. Mice lacking IL-6
showed no difference in both infarct size and neurological function
24 hours following MCAO [20], whereas clinical studies report a
worsening influence of elevated serum IL-6 in stroke patients
[21,22]. Findings of another study even showed an anti-apoptotic
and neuroprotective effect of endogenous IL-6 on oxygen
deprivated neurons following MCAO [23]. Our findings reveal
an extensive breakdown of IL-6-transcription in MCP-1-deficient
mice. This could be explained by results of previous studies, which
showed that activation of the interleukin-6 receptor IL-6R induces
MCP-1 expression and further secretion of IL-6. This creates an
autocrine stimulation loop via the JAK/STAT signal transduction
pathway for both IL-6 and MCP-1, the latter resulting in an
autocrine induction via its receptor CCR-2 [24,25]. Our results
indicate that a lack of MCP-1 constrains these loops, resulting in a
reduced expression of IL-6 in neurons and astrocytes within the
ipsilateral cortex and ischemic striatum.
Interleukin-1b has been shown to negatively contribute to
ischemic, excitotoxic and traumatic brain injury. Intraventricular
injection of IL-1b excacerbates brain damage following occlusion
of the middle cerebral artery [4], while immuno-neutralization of
IL-1b leads to smaller infarcts [26]. Our results show that lack of
MCP-1 impairs IL-1b expression especially within the ischemic
core 12 hours after onset of cerebral ischemia, which is in
agreement with findings of previous studies demonstrating a causal
relationship between diminished IL-1b and smaller infarct sizes
[27,28]. Furthermore, a recent study reported a direct link
between activation of JAK/STAT pathway and subsequent
induction of IL-1b and IL-6 in murine macrophages. In
accordance with our findings, induction of latter signal transduc-
tion pathway led to an elevated IL-1b and IL-6 production but
failed to induce TNF-a [29].
Figure 6. MCP-1-deficiency leads to an impaired influx of
neutrophil granulocytes and T-cells. (A) Quantitative assessment
of migrated neutrophils within ipsilateral cortex (cor, fig.1 A) following
30 min transient middle cerebral artery occlusion. Values are obtained
counting the absolute number of cortical 7/4-positive cells in 8 sections
per animal. Twelve hours after MCAO, MCP-1-deficient mice showed an
impaired influx of neutrophil granulocytes within the ipsilateral cortex
compared to wildtype controls (*p,0.001). (B) Quantitative analysis of
T-cell migration within the ipsilateral cortex of MCP-1-deficient and
wildtype mice. Thirty-six hours after MCAO T-cell numbers were
significantly lower in MCP-1-deficient animals. (C) Immunohistochem-
istry of neutrophil granulocytes within the ipsilateral cortex. Represen-
tative 7/4 stained image taken from a wildtype animal. Following
transient cerebral ischemia most neutrophil granulocytes were found
within the meningeal layers and the cortical tissue. Scale bar=100 mm.
(D) T-cell within the ipsilateral cortex of a wildtype mouse. Arrowheads
mark the border of a blood vessel. Nuclear counterstain with DAPI
(blue). Scale bar=25 mm.
doi:10.1371/journal.pone.0025863.g006
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post stroke inflammatory response including downregulation of
interleukin-1b and reduction of edema formation [30,31]. Several
other studies showed further beneficial effects of G-CSF-treatment
following experimental cerebral ischemia such as reduced infarct
volume, improved functional outcome, neurogenesis and anti-
apoptotic effects [32,17,18]. Surprisingly, we found that G-CSF
transcription is downregulated in MCP-1-deficient mice within the
ipsilateral cortex. However, these results are in accordance with our
findings of a diminished influx of neutrophil granulocytes within the
ipsilateral cortex of MCP-1-deficient mice as neutrophil prolifera-
tion and migration is mainly driven by G-CSF [33]. Following
cerebral ischemia, neutrophil migration has been shown to be a
critical factor in subsequent damage development. Several studies
report deleterious contribution concerning neutrophil action in
brain damage pathology for instance by secreting matrix metallo-
proteinases which degrade extracellular matrix and blood-brain-
barrier (BBB) proteins, resulting in disruption of BBB integrity,
aggravation of edema formation, hemorrhagic transformation
and inflammation [34,35,36]. Numerous publications describe a
relationship between the number of attracted neutrophils, final
infarct volume and neurological outcome in which less neutrophils
denoted a milder course of disease [37,38]. This is in accordance
with our findings and previous reports [6] revealing an impaired
influx of neutrophil granulocytes in MCP-1-deficient mice.
Since T-lymphocyte action has been reported to aggravate post
ischemia lesion size [39], we also investigated a possible influence
of MCP-1 on the migration of T-cells. Indeed, mice lacking MCP-
1 showed an impaired influx of T-cells 36 hours after cerebral
ischemia. As TNF-a is an important factor for T-lymphocyte
activation and response [40] the diminished influx of T-cells in
MCP-1-deficient mice could be explained by the reduced cell
number expressing TNF-a within the infarcted core 12 hours after
MCAO. However, we did not found an altered expression profile
of TNF-a comparing the investigated groups. There is evidence
that JAK/STAT signalling directly induces MCP-1 expression via
binding of STAT to the MCP-1 promotor [25]. Since expression
and induction of IL-6, IF-1b and G-CSF are also connected to the
JAK/STAT signal transduction pathway, shifting towards a less
inflammatory state in MCP-1-deficient mice could be due to an
interruption of JAK/STAT-dependent autocrine loops. Especially
during the early post ischemic phase, this might result in smaller
infarct volumes, reduced loss of BBB integrity, less influx of
hematogenous cells and improved neurological outcome in MCP-
1-deficient mice.
Although it is not possible to clarify all mechanisms associated
with smaller infarcts, neuroprotective effects and improved clinical
outcome in MCP-1-deficient mice, we can conclude that the
induction of inflammation-related cytokines such as IL-6, IF-1b
and G-CSF is impaired in MCP-1-deficient mice during the
early inflammatory phase, resulting in a decreased migration of
hematogenous cells and reduced lesion size.
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